ERBB2 and breast cancer: Primary outcome: Change in the percent of stromal cells expressing Cav-1 at an intensity of 1 + or greater assessed by immunohistochemistry Secondary outcome: Percentage of stromal cells expressing Cav-1 in relation to the percentage of cells expressing ER and PR for breast and uterine samples and HER2 in breast cancer samples.